Publication of the Day
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Science, November 23, 2021
- In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection.
- All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy.
- Vaccine recipients with post-vaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacy of 78%, 91%, and 96%, respectively.
- These results help define immune marker correlates of protection and may guide approval decisions for mRNA COVID-19 vaccines and other COVID-19 vaccines.
Publications
- Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
Nature Communications, November 18, 2021 - Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet, November 17, 2021 - Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
The Lancet Microbe, November 15, 2021 - Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
The Lancet, November 11, 2021 - Evaluation of the BNT162b2 Vaccine against Covid-19 in 5-to-11-Year-Olds
NEJM, November 9, 2021 - A novel SARS-CoV-2 related coronavirus in bats from Cambodia
Nature Communications, November 9, 2021 - Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles
Science, November 4, 2021 - Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
NEJM, November 3, 2021 - COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women
Science Translational Medicine, October 19, 2021 - Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
The Lancet Global Health, October 27, 2021
News
- World Health Organization declares new variant of concern named omicron
CBC, November 26, 2021 - What do we know about the new ‘worst ever’ Covid variant?
The Guardian, November 26, 2021 - The U.S. will restrict travel from South Africa and seven other African countries to contain the new variant of the coronavirus, officials said.
NYT, November 26, 2021 - Omicron: New COVID variant pushes EU countries to restrict air travel from southern Africa
Euronews, November 26, 2021 - Merck’s COVID-19 pill significantly less effective in new analysis
Reuters, November 26, 2021 - Covid-19: 95.9% of adult population in Malaysia fully vaccinated as of Nov 25
The Edge Markets, November 26, 2021 - COVID in Germany: Incidence rate hits 400 for first time
Deutsche Welle, November 24, 2021 - COVID cases break records in Europe, prompting booster shot expansion
Reuters, November 24, 2021 - Covid-19 cases are on the rise with Thanksgiving just a day away (US)
CNN, November 24, 2021 - New Zealand to reopen borders to vaccinated travelers in 2022
CNN, November 24, 2021 - In Spain, elderly 25 times more at risk of dying from Covid-19 if unvaccinated
El Pais, November 24, 2021 - Slovakia becomes the second European country to go into lockdown as COVID cases surge
Euronews, November 24, 2021